Title: Analysis of adjuvant endocrine therapy on the prognosis of endometrial carcinoma confined to the uterus
Abstract: International Journal of Gynecology & ObstetricsVolume 98, Issue 2 p. 162-163 Brief communications Analysis of adjuvant endocrine therapy on the prognosis of endometrial carcinoma confined to the uterus Zhiqi Wang, Zhiqi Wang Center of Gynecologic Oncology, Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, ChinaSearch for more papers by this authorJianliu Wang, Corresponding Author Jianliu Wang [email protected] [email protected] Center of Gynecologic Oncology, Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, China⁎Corresponding author. Center of Gynecologic Oncology, Peking University People's Hospital, No 11, Xizhimen South Street, Beijing 100044, China. Tel.: +86 10 68792680; fax: +86 10 68318386.Search for more papers by this authorLihui Wei, Lihui Wei Center of Gynecologic Oncology, Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, ChinaSearch for more papers by this author Zhiqi Wang, Zhiqi Wang Center of Gynecologic Oncology, Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, ChinaSearch for more papers by this authorJianliu Wang, Corresponding Author Jianliu Wang [email protected] [email protected] Center of Gynecologic Oncology, Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, China⁎Corresponding author. Center of Gynecologic Oncology, Peking University People's Hospital, No 11, Xizhimen South Street, Beijing 100044, China. Tel.: +86 10 68792680; fax: +86 10 68318386.Search for more papers by this authorLihui Wei, Lihui Wei Center of Gynecologic Oncology, Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, ChinaSearch for more papers by this author First published: 22 June 2007 https://doi.org/10.1016/j.ijgo.2007.05.008Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References [1]Wang Z.Q., Wang J.L., Guo J., Wei L.H. Clinical significance of adjuvant endocrine therapy in treatment of endometrialcarcinoma: study of 171 patients [In Chinese]. Zhonghua YiXue ZaZhi. 85(34): 2005; 2414– 2419 [2]Von Minckwitz G., Loibl S., Brunnert K., Kreienberg R., Melchert F., Mosch R., et al. Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer: a multicentre, open, controlled, prospectively randomised trial. Eur J Cancer. 38(17): 2002; 2265– 2271 [3]Piver M.S., Recio F.O., Baker T.R., Hempling R.E. A prospective trial of progesterone therapy for malignant peritoneal cytology in patients with endometrial carcinoma. Gynecol Oncol. 47(3): 1992; 373– 376 [4]Vishnevsky A.S., Bokhman Ya. V., Loutfi G. Favourable influence of adjuvant hormone therapy by oxyprogesterone caproate (OPC) and by its combination with tamoxifen of 5-year survival rate of surgical and combined treatment of primary endometrial carcinoma patients. Eur J Gynaecol Oncol. 14(2): 1993; 150– 153 Volume98, Issue2August 2007Pages 162-163 ReferencesRelatedInformation
Publication Year: 2007
Publication Date: 2007-06-22
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot